Searchable abstracts of presentations at key conferences in endocrinology

ea0028pl9 | Clinical Endocrinology Trust Visiting Professor Lecture | SFEBES2012

Long-term outcome and quality of life in patients with disorders of sex development

Mendonca Berenice

This study aimed to identify variables involved in gender identity and sexual orientation, as well as to evaluate the professional and psychosocial aspects and quality of life in adulthood of a large cohort of patients with 46,XY and 46,XX DSD followed by a multidisciplinary team in a tertiary public hospital in Brazil. The study was mainly retrospective and comprised 151 DSD patients; 55 patients had 46,XX and 96 had 46,XY karyotypes. Etiological diagnosis of DSD was establis...

ea0028pl9biog | Clinical Endocrinology Trust Visiting Professor Lecture | SFEBES2012

Clinical Endocrinology Trust Visiting Professor Lecture

B Mendonca Berenice

Berenice B Mendonca, University of Sao Paulo, Brazil AbstractBerenice B Mendonca received her M.D in 1973 from Faculdade de Medicina do Triangulo Mineiro, Brazil. In 1984, Prof Mendonca completed her research fellowship in Endocrinology at the University of Sao Paulo School of Medicine, where she developed the whole of her scientific achievements.During the course of her career, Prof Mendonca ha...

ea0063p1146 | Reproductive Endocrinology 2 | ECE2019

Recurrent reversal of male congenital hypogonadotropic hypogonadism and atypical fertility: A case report.

Renck Alessandra , Rocha Michelle , Amato Lorena , Schnoll Caroline , Sales Priscila , Latronico Ana , Mendonca Berenice , Costa Elaine , Silveira Leticia

Abstract: Congenital hypogonadotropic hypogonadism (CHH) is characterized by isolated GnRH deficiency in the absence of central anatomical causes. Classically considered to be a permanent disorder, CHH reversal has been reported in up to 15% of cases. However, reversal may not always be life-long, as hypogonadism relapse can occur in a subset of patients. Criteria for reversal normalization of circulating sex steroids, and spontaneous fertility. We report a 26-yrs-old man, who...

ea0081ep880 | Reproductive and Developmental Endocrinology | ECE2022

Cardiopulmonary capacity and muscle strength in transgender women in long-term gender-affirming hormone therapy: a cross-sectional study

Alvares Leonardo , Santos Marcelo Rodrigues dos , Souza Francis Ribeiro de , Santos Livia Marcela , Costa Elaine Maria Frade , Bilharinho de Mendonca Berenice , Alves Maria Janieire de Nazare Nunes , Domenice Sorahia

Introduction: Effects of prior exposure to testosterone (T) during puberty on the performance of transgender women (TW) in estrogen therapy undergoing physical effort are not known, mainly about cardiopulmonary capacity (CPC). Objectives: To evaluate CPC and muscle strength in TW undergoing long-term gender-affirming hormone therapy (GAHT). Methods: A cross-sectional study was carried out with 15 TW (34.2±5.2 yo), 13 cisgender men (CM) and 14 cisgender women (CW). TW were i...

ea0086p343 | Neuroendocrinology and Pituitary | SFEBES2022

Variants in Methyl-CpG-binding protein 2 (MECP2) are associated with X-Linked Central Precocious Puberty

E Read Jordan , Pinheiro-Machado Canton Ana , Tinano Flavia , Guasti Leonardo , Ribeiro Montenegro Luciana , Ryan Fiona , Shears Deborah , Paganoni Alyssa , Korbonits Marta , Jorge Alexander , David Alessia , Bilharinho Mendonca Berenice , Nahime Brito Vinicius , Claudia Latronico Ana , Howard Sasha R

Whilst several key genetic contributors to the phenotype of central precocious puberty (CPP) have been recognized, many familial cases remain without a clear genetic aetiology. Methyl-CpG-binding protein 2 (MECP2) is a chromatin-associated transcriptional regulator, which plays an essential role in neuronal maturation. It is encoded by the MECP2 gene, located at chromosome Xq28, which is highly expressed in brain tissues. Loss-of-function mutations in MECP2 are usually associa...

ea0041ep14 | Adrenal cortex (to include Cushing's) | ECE2016

Adrenal crisis and sick day episodes among CAH patients: preliminary report based on international CAH (I-CAH) registry

Karunasena Nayananjani , Daniel Eleni , Bryce Jillian , Jiang Jipu , Faisal Ahmed S , Guran Tulay , Mendonca Berenice B , Bachega Tania A , Blankenstein Oliver , Koehler Birgit , Neumann Uta , Acerini Carlo , Krone Nils , Bonfig Walter , Mohnike Klaus , Elsedfy Heba , Ross Richard

Background: Congenital adrenal hyperplasia (CAH) is a rare condition that is associated with life long risk of adrenal crisis. Management of CAH demands a fine balance between excess glucocorticoid leading to adverse effects and too little glucocorticoid risking adrenal crises. Frequent occurrence of sick day episodes warrants dose adjustment and education regarding adrenal crisis. In a condition such as CAH it is difficult to collect sufficient data from small cohorts at a si...

ea0063gp197 | Adrenal and Neuroendocrine - Clinical | ECE2019

Optimizing mineralocorticoid replacement therapy in patients with congenital adrenal hyperplasia and Addison’s disease

Pofi Riccardo , Prete Alessandro , Thornton-Jones Vivien , Bryce Jilian , Ali Salma , Ahmed Faisal , Koehler Birgit , Balsamo Antonio , Acerini Carlo , Cannuccia Amalia , Guven Ayla , Guran Tulay , Darendeliler Feyza , Higham Claire , Bonfig Walter , De Vries Liat , Mendonca Berenice B , Iotova Violeta , Krone Nils P , Krone Ruth , Lenzi Andrea , Arlt Wiebke , Ross Richard , Isidori Andrea M , Tomlinson Jeremy W

Background: Adrenal insufficiency (AI) results from deficient production/action of glucocorticoids (GCs), with or without deficiency of mineralocorticoids (MC) and adrenal androgens. GC treatment is essential but some patient needs MC therapy to allow sodium(Na+) retention, potassium(K+) excretion and to maintain normal plasma volume and blood pressure. Much attention has focused on optimization of GC replacement but no consensus exists for optimization o...

ea0066oc1.1 | Oral Communications 1 | BSPED2019

Exploring trends in the glucocorticoid and mineralocorticoid treatment of congenital adrenal hyperplasia by analysing data from the I-CAH registry

Bacila Irina-Alexandra , Blankenstein Oliver , Neumann Uta , Grinten Heidi L Claahsen-van der , Krone Ruth , Bachega Tania SS , Miranda Mirela C , Mendonca Berenice , Birkebaek Niels H , Cools Martine , Milenkovic Tatjana , Bonfig Walter , Tomlinson Jeremy W , Elsedfy Heba , Balsamo Antonio , Ortolano Rita , Hannema Sabine , Higham Claire , Atapattu Navoda , Lichiardopol Corina , Guran Tulay , Abali Zehra , Mohnike Klaus , Finken Martijn JJ , Vieites Ana , Darendeliler Feyza , Guven Ayla , Korbonits Marta , Vries Liat de , Costa Eduardo , Einaudi Silvia , Kamp Hetty van der , Iotova Violeta , Ross Richard , Ahmed S Faisal , Krone Nils

Introduction: There is no unified approach in clinical practice regarding the medical management of congenital adrenal hyperplasia (CAH), despite existent international guidance. We aimed to explore geographical and temporal variations in the treatment with glucocorticoids and mineralocorticoids of patients with CAH.Methods: We collected data recorded by 33 centres from 16 countries in the I-CAH Registry. We analysed patient visits between 1982 and 2018,...